Platinum/ 5 Fluoracil in recurrent and/or metastatic disease in head and neck carcinoma
Abstract
Introduction: Among all neoplasms, those of the head and neck represent 4 % of all malignant processes. More than half of patients with advanced loco regional disease will relapse or have treatment failure. Overall survival is between 6-9 months when treated with chemotherapy.
Objective: To determine the overall survival, response rates, and toxicities of the platinum/5-fluorouracil treatment scheme in the recurrent or metastatic scenario of patients with head and neck carcinoma.
Methods: A descriptive, cross-sectional and retrospective study was carried out at the Institute of Oncology and Radiobiology. The universe was made up of all patients enrolled from 2015 to 2017 with a diagnosis of squamous cell carcinoma of the head and neck area who were in the recurrent and/or metastatic stage, the sample was made up of 69 patients who received the combination of platinum salts. / 5-fluorouracil in the first line.
Results: Patients between 50-69 years represented 73.9 %, the larynx was the most frequent anatomical site 40.6 %, 71 % of the patients were diagnosed in an advanced stage, 48 % presented persistence of the disease and predominated local relapse. The objective response was 23.4 %. The most frequent toxicities were hematological and the median overall survival was 10 months with a 95 % CI confidence interval (9.33-10.66).
Conclusions: The Platinum/5Fluoracil combination remains the first-line treatment standard in this setting.
Downloads
References
1. Cramer J, Burtness B, Thu Lee Q Ferris L. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology, 2019; 16,669-683.
2. Chaudhary S, Ganguly K, Muniyan S, Pothuraju R, Sayed Z, Jones D, et al. Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity. JNCI J Natl Cancer Inst, 2019, Vol. 111, No. 3. doi: 10.1093/jnci/djy207.
3. McDermott JD, Bowles DW. Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies. Curr Treat Options Oncol. 2019; 20 (5): 43. doi: 10.1007/s11864-019-0650-5
4. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71:7. DOI: 10.3322/caac.21654
5. Dong H, Shu X, Xu Q, Zhu CH, Kaufmann A, Zheng Z et al. Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care. Virologica Sinica (2021) 36:1284–1302. doi.org/10.1007/s12250-021-00413-8.
6. Konings H, Stappers S, Geens M, Winter B, Lamote K, Meerbeeck J, et al. A literature review of the potential diagnostic biomarkers of head and neck neoplasms. Frontiers in Oncology June 2020 | Volume 10 | Article 1020. doi: 10.3389/fonc.2020.01020.
7. García San JC, Salas Rodríguez M, Gil Milá J. Some considerations on etiology and pathophysiology of oral epidermoid carcinoma. Medisur. 2018 ; 16( 1 ): 63-75. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2018000100010&lng=es.
8. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394-424. doi: 10.3322/caac.21492
9. Pulte D, Brenner H. Changes insurvival in head and neck cancers in the late 20th and early 21st century: a period analysis. The Oncologist 2010; 15:994–1001. doi: 10.1634/theoncologist.2009-0289
10. Johnson D E, Burtness B, Leemans C R, Yan Lui V W, Bauman J E , Grandis J R . Head and neck squamous cell carcinoma. NATURE REVIEWS | Disease Primers.(2020) 6:92.https://doi.org/10.1038/s41572-020-00224-3
11. http://bvscuba.sld.cu/anuario-estadistico-de-cuba/. 2021 ISSN: versión electrónica 1561-4433. Cuadro 42 y 43 mortalidad por tumores malignos en el sexo masculino y femenino según localización y grupo de edad 2019.
12. http://bvscuba.sld.cu/anuario-estadistico-de-cuba/. 2021 ISSN: versión electrónica 1561-4433. Cuadro 78 incidencia de cáncer según sexo y principales localizaciones .2018..
13. Magnes T, Egle A, Greil R, Melchardt T. Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017. Memo 2017; 10: 220–23. DOI: 10.1007/s12254-017-0358-9
14. DeVita T, Lawrence Th S, Rosenberg S A.DeVita, Hellman, and Rosenbergscancer: principles &practice of oncology.11th ed. Philadelphia: Wolters Kluwer; 2019.
15. Srinivasalu V, Narayana S, Balasubramanian D, Kumar N, Philip A, Susan A, et al. Concurrent chemotherapy for head and neck cancer in older patient: Outcomes and their determinants. Indian Journal of Cancer. Vol 56(3):261-266.July-September 2019. Doi:10.4103/ijc.ijc_725_18
16. Lop J, Valero C, García J, Quer M, Ganly I, Shah J, et al. Does age influence disease-specific survival in patients with squamous cell carcinomas of the head and neck. J Surg Oncol. 2020 June; 121(7): 1058–1066. doi:10.1002/jso.25895.
17. Lacas B, Carmel A, Landais C, Wong S, Licitra L, Tobia J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACHNC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021 March; 156: 281–293. doi:10.1016/j.radonc.2021.01.013.
18. Kish JA, et al. The effect of age on outcome in prospective, phase III NRG Oncology/ RTOG trials of radiotherapy (XRT) +/− chemotherapy in locally advanced (LA) head and neck cancer (HNC). J ClinOncol 2015;33(Suppl.; abstr 6003. DOI: 10.1200/jco.2015.33.15
19. Jiang H, Livingston M, Room R, Gan Y, English D, Chenhall R. Can public health policies on alcohol and tobacco reduce a cancer epidemic? Australia’s experience. BMC Medicine (2019) 17: 213. https://doi.org/10.1186/s12916-019-1453-z.
20. Del Mistro A, rayle H, Menegaldo A, favaretto N, Gori S, nicolai P, et al. Age-independent increasing prevalence of Human papillomavirus-driven oropharyngeal carcinomas in north-east italy. Scientific RepoRtS | (2020) 10:9320 | https://doi.org/10.1038/s41598-020-66323-z
21. Argiris A, Li S, Savvides P, James P, Gilbert J,Levine M, et al. Phase III Radomised trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck.J Clin Oncol
2019;37(34):3266-3274.Doi.org/10.1200/JCO.19.00555
22. Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez G,et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitor in patient with recurrent and/or metastatic squamous cell carcinoma of head and neck. I European Journal of cancer 121(2019) 123-129.http:doi.org/10.1016/j.ejca.2019.08.026
23. Robles Santos J, Pérez García T, Iznaga Marín N, Contreras PJ. Caracterización clínica del cáncer de cabeza y cuello. Rev Cubana OtorrinolaringolCirug Cabeza Cuello. 2020; 4 (1). Disponible en: http://www.revotorrino.sld.cu/index.php/otl/article/view/128
24. Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, et al. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019; 28 (10): 1660-1667. Doi: 10.1158/1055-9965.EPI-19-0038.
25. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359 (11): 1116-27. doi: 10.1056/NEJMoa0802656.
26. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo ClinProc. 2016; 91 (3): 386-96. doi: 10.1016/j.mayocp.2015.12.017.
27. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfer H, Pajak TE et al. Long term results of RTOG 91-11: A comparison of three non-surgical strategies to preserve the Larynx in patients with locally advanced larynx cancer. J. ClinOncol 2012;31:845-852. DOI: 10.1200/JCO.2012.43.6097
28. Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, et al. Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck. 2019; 41 (6): 1895-1902. doi: 10.1002/hed.25636
29. Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter TH, Tavassoli M. Clinical update on head and neck cancer: molecular biology and ongoing challenges.Official journal of the Cell Death Differentiation Association. doi.org/10.1038/s41419-019-1769-9.
30. Leon X, Quer R, Orus C., del Prado Venegas M, Lopez M. Distant metastases in head and neck cancer patients who achieved loco-regional control .head neck 2000:22:680-6.http://doi.org/10.1002/1097-0347(200010)22:7˂680:aid-hed7˃3.0c0:2-j.
31. Ghosh S, Shah P, Johnson F, Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Int. J. Mol. Sci. 2022, 23, 7889. https://doi.org/10.3390/ijms23147889.
32. Pisani P, Airoldi M, Allais A, Valletti P, Battista M, Benazzo M, et al. Metastatic disease in head & neck oncology. ACTA OTORHINOLARYNGOLOGICA ITALICA 2020;40(SUPPL.1):S1-S86; doi: 10.14639/0392-100X-suppl.1-40-2020
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
